Pterygopalatine fossa nerve block for headaches after subarachnoid hemorrhage

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

BLOCK-SAH is a phase II clinical trial that investigates the effectiveness of bilateral pterygopalatine fossa injections using ropivacaine and dexamethasone compared to a saline placebo in treating headaches in patients who have survived an aneurysmal subarachnoid hemorrhage. The study employs a randomized, double-blinded, placebo-controlled design and monitors intracranial arterial mean flow velocities using transcranial Doppler ultrasound during the intervention. Participants must be admitted with a primary diagnosis of spontaneous, non-traumatic SAH within 48 hours of the hemorrhage. The trial aims to assess the potential benefits of this nerve block technique in alleviating post-SAH headaches.

Why it matters

Who can join: the full rules

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

1. Provision of signed and dated ICF by participant or a legally authorized representative (LAR)
2. Stated willingness to comply with all study procedures and availability for the duration of the study
3. Male or female, aged ≥18 and ≤ 85 years
4. Admitted with a primary diagnosis of spontaneous, non-traumatic, SAH within 72 hours of ictus hemorrhage
5. Disease-specific inclusion criteria:

   1. Spontaneous, non-traumatic SAH
   2. Subarachnoid pattern of hemorrhage warranting diagnostic DSA due to involvement of at least one of the following regions: quadrigeminal plate, prepontine cistern, perimesencephalic cistern, Sylvian fissure, or surrounding Circle of Willis
   3. Modified Fisher grade 1-4 (on presentation imaging)
   4. Hunt and Hess 1-3 or World Federation of Neurosurgeons grade 1-4 (on screening, included only if also fulfilling Glasgow Coma Scale verbal subscore ≥4)
   5. Minimum Glasgow Coma Scale verbal subscore of 4 (on screening)
6. Able to verbalize pain scale scores according to 11-point numeric pain scale

   In order to be enrolled and undergo randomization in this study, an individual must meet all of the additional criteria:
7. Stabilization period criteria:

   1. A minimum of 4 hours from DSA with clipping or coiling procedure (whenever applicable)
   2. Successful treatment of culprit vascular lesion (i.e., ≥90% obliteration of aneurysm), when applicable
8. Requiring a minimum of 15mg OME prn for headache analgesia during any 24-hour period during eligibility period

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

1. Premorbid conditions:

   1. Pre-existing neurologic, psychiatric, or other condition that would confound neurologic assessment or would make difficult/impossible to accurately assess neurologic and/or functional outcome
   2. Pre-existing diffuse flow-limiting narrowing of arteries in the Circle of Willis, regardless of etiology (e.g., atherosclerosis, vasculitis, Moya-Moya syndrome)
   3. Prior use of opioid or barbiturate analgesics for at least two-thirds of the days in previous month, regardless of indication
   4. Diagnosis of substance use disorder in the previous year
   5. Infected or wounded skin, or a skin lesion at the site of puncture for PPF- injection
2. Uncorrected coagulopathy

   1. Platelet count \< 50,000/μL, International Normalized Ratio (INR) \> 1.7
   2. Requiring use of systemic anticoagulation and antiplatelet therapy (except for aspirin monotherapy).
3. SAH-specific:

   1. Head trauma as etiology of SAH
   2. Infection as cause for aneurysm or SAH (i.e., mycotic aneurysms)
   3. Inability to successfully treat culprit vascular lesion
   4. Diffuse vasospasm on pre-enrollment diagnostic CTA or DSA. Vasospasm is defined as moderate-to-severe arterial narrowing on DSA or CTA not attributable to atherosclerosis, catheter-induced spasm, or vessel hypoplasia, as determined by a neuroradiologist or neurointerventionalist
4. Standard pain regimen conditions

   1. Elevation of hepatic enzymes prohibiting use of scheduled APAP (i.e., AST or ALT \> 3x upper limit level)
   2. Chronic liver condition with absolute contra-indication for APAP (even at lower maximum daily doses)
5. Participation in a concurrent investigational/interventional study (observational studies allowed)
6. Known to be pregnant, or with a positive pregnancy test
7. Allergy or intolerance to the medications used in the PPF-block (i.e., ropivacaine, dexamethasone) or standard pain regimen (APAP)
8. Vulnerable populations such as prisoners and inmates (abiding GCP per the study IRB)
9. Unable to receive first PPF-injection within 96 hours of ictus hemorrhage

Where it's running

• University of Florida
  Gainesville, Florida, United States Recruiting
• University of Miami
  Miami, Florida, United States Recruiting
• Cleveland Clinic Foundation Martin Health
  Stuart, Florida, United States Recruiting
• Emory University
  Atlanta, Georgia, United States Recruiting
• University of Maryland Baltimore
  Baltimore, Maryland, United States Recruiting
• Creighton University Medical Center
  Omaha, Nebraska, United States Recruiting

Study contacts

• Study coordinator: Yurerkis Montas
• Email: ymontas@partners.org
• Phone: 617-866-9758

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Lidocaine with or without steroid infusion into the middle meningeal artery for headaches after aneurysmal subarachnoid hemorrhage

  This study will try an infusion of lidocaine, with or without a steroid, into the middle meningeal artery to see if it reduces severe headaches and opioid use in adults recovering from aneurysmal subarachnoid hemorrhage.

  Recruiting Phase 2 The University of Texas Medical Branch, Galveston · Galveston, Texas · NCT07294118

• Understanding hemorrhage subtypes in perimesencephalic SAH and basilar artery perforator aneurysms

  This study tests whether different bleeding patterns in pmSAH, including potential basilar artery perforator aneurysms, relate to patient outcomes using a patient-reported EQ-5D measure.

  Recruiting Insel Gruppe AG, University Hospital Bern · Bern · NCT07923084

• HEADS Registry: Headache, Ear, Auditory, Dizziness, and Sinus</n> Registry

  This registry tests whether collecting online symptom reports from adults in the U.S. with sinus, vestibular, ear, or headache symptoms can help improve diagnosis and treatment.

  Recruiting Association of Migraine Disorders · North Kingstown, Rhode Island · NCT07754266

• Immediate neck manual therapy effects on atlas position and neck muscles

  This trial tests two upper neck manual therapy techniques to see their immediate effect on neck alignment, atlas position, and a neck muscle shape in adults with head and neck pain or headaches.

  Recruiting Florida Gulf Coast University · Fort Myers, Florida · NCT07725198

• Vitamin IV lidocaine before fundal pressure to prevent headache after cesarean using spinal anesthesia

  This trial tests whether a single intravenous dose of lidocaine given before fundal pressure during cesarean delivery reduces the chance or severity of headache.

  Recruiting Phase 3 Tanta University · Tanta, Gharbia Governorate · NCT07661758

• Muscle Position and Dry Needling Efficacy

  This study tests whether the position of the upper trapezius during dry needling changes pain and function for people with chronic neck pain.

  Recruiting at 2 sites University of Alcala · Alcalá de Henares, Madrid and 1 other locations · NCT07629141

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.